Lipoprotein apheresis involves the extracorporeal removal of LDL and lipoprotein(a) particles from whole blood or plasma by adsorption, precipitation or differential filtration. Used repetitively ...

How a synthetic lipoprotein targets tumor metabolism to trigger cancer cell death by Olivia Dimmer, Northwestern University edited by Lisa Lock, reviewed by Robert Egan Editors' notes ...

A new study has found that apolipoprotein B particle count and lipoprotein(a) count were critical indicators of risk for coronary artery disease related to cholesterol.

Deciding whether to start hormone therapy during the menopause transition, the life phase that's the bookend to puberty and when a woman's menstrual cycle stops, is a hotly debated topic. While ...

A new drug can potentially significantly reduce levels of lipoprotein (a), a type of undetected cholesterol that can spike the risk of heart disease.

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% ...

Lilly saw sustained reductions for nearly 1.5 years, bolstering its argument that the siRNA candidate has an edge over rivals from Amgen and Novartis.

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be untreatable, for up to one year. Lipoprotein(a) is a type of cholesterol that ...

The FDA cleared a new lipoprotein assay designed to measure lipoprotein (a) in nmol/L. Measuring nmol/L rather than mg/dL may improve diagnostic accuracy during CV risk assessment.

There is no approved treatment for high lipoprotein(a), but five drugs are in development, and last fall, two of them moved a step closer to consideration by the FDA.

ApoB100 is a key protein in normal metabolism and in heart disease. Beginning before the protein’s synthesis is completed, it collects cholesterol and fats into particles that allow these ...